These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 30712480)

  • 1. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
    Ho DH; Kim H; Kim J; Sim H; Ahn H; Kim J; Seo H; Chung KC; Park BJ; Son I; Seol W
    Mol Brain; 2015 Sep; 8():54. PubMed ID: 26384650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
    Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
    Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
    Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
    J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells.
    Ho DH; Nam D; Seo MK; Park SW; Seol W; Son I
    Oxid Med Cell Longev; 2021; 2021():9969842. PubMed ID: 34306319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
    Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
    Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.
    Cresto N; Gardier C; Gaillard MC; Gubinelli F; Roost P; Molina D; Josephine C; Dufour N; Auregan G; Guillermier M; Bernier S; Jan C; Gipchtein P; Hantraye P; Chartier-Harlin MC; Bonvento G; Van Camp N; Taymans JM; Cambon K; Liot G; Bemelmans AP; Brouillet E
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.
    Ho DH; Seol W; Eun JH; Son IH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1088-1094. PubMed ID: 27914807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
    Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
    Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.